Journal Article

An Overview of the Susceptibility Testing of Pharyngeal Group A Streptococcus Pyogenes

Fatemah Mohamad Hussin Namazi, Sana Mohsen Abo Eid, Albasrawi, Meshary Waheeb, Amro Abdullah Alghamdi, Suwaylih Ayidh Saleh Al Juaid, Mohammed Fawaz Alghufayri, Maha Hussein Shararah, Rayan Faisal Khyami, Samer Muidh W Alsulami, Faisal Ahmad Tashkandi, Rayan Hasan Abdelah Alqurashi, Mohammed Ahmed Mohammed Almalki, Juhali, Faisal Yhaya, Faisal Masoud Alshalihi, Saad Fawaz Bin Khatim Alghufairy

2024

Overview

Group A Streptococcus pyogenes (GAS), a β-hemolytic Gram-positive bacterium, is one of the most significant human pathogens globally. It is the primary causative agent of bacterial pharyngitis, a common condition that affects millions of individuals annually, particularly children aged 5–15 years. GAS pharyngitis accounts for approximately 20–30% of sore throat cases in pediatric populations and 5–15% in adults [1]. The clinical relevance of GAS infections extends beyond the acute illness, as untreated or inadequately treated pharyngitis can lead to immune-mediated complications such as acute rheumatic fever, rheumatic heart disease, and post-streptococcal glomerulonephritis, all of which pose substantial public health burdens, particularly in low-resource settings [2,3].

• Publisher: Nicholson School of Communication and Media at the University of Central Florida
• Subject: Antibiotics / Antimicrobial agents / Automation / Bats / Drug resistance / Failure / Genes / Hospitals / Medical laboratories / Methods / Penicillin / Public health / Regions / Streptococcus infections / Supply chains / Trends